Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Why Tellurian Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket

Published 26/01/2024, 12:58
© Reuters.  Why Tellurian Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

Shares of Tellurian Inc. (NASDAQ: TELL) shares rose sharply in pre-market trading following a report suggesting the company hired Lazard to explore a possible sale.

Tellurian shares jumped 16.3% to $0.6050 in pre-market trading

Here are some other stocks moving in pre-market trading.

Gainers

  • Inspire Veterinary Partners, Inc. (NASDAQ: IVP) gained 99.9% to $0.3817 in pre-market trading after jumping over 22% on Thursday.
  • Jaguar Health, Inc. (NASDAQ: JAGX) gained 29.1% to $0.1485 in pre-market trading after gaining around 12% on Thursday.
  • TC Biopharm (Holdings) Plc (NASDAQ: TCBP) shares jumped 27.2% to $2.22 in pre-market trading following a 15% decline on Thursday.
  • RiskOn International, Inc. (NASDAQ: ROI) gained 21.8% to $0.1481 in pre-market trading after gaining over 9% on Thursday.
  • Vision Marine Technologies Inc. (NASDAQ: VMAR) shares climbed 19.7% to $0.9530 in pre-market trading.
  • Cyngn Inc. (NASDAQ: CYN) surged 16.3% to $0.25 in pre-market trading. Cyngn shares jumped over 17% on Thursday after the company disclosed a strategic shift to Nvidia AI computers that will transform the technology powering its fleet of DriveMod autonomous industrial vehicles.
  • WANG & LEE GROUP, Inc. (NASDAQ: WLGS) shares gained 14.1% to $0.7070 in pre-market trading.
  • Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) shares rose 10.7% to $1.44 in pre-market trading after gaining over 5% on Thursday.
  • InflaRx N.V. (NASDAQ: IFRX) shares gained 9.3% to $1.64 in pre-market trading after falling over 6% on Thursday. InflaRx recently reported topline results from the multiple ascending dose Phase 1 study with C5aR inhibitor INF904.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .
Losers
  • Aptose Biosciences Inc. (NASDAQ: APTO) shares dipped 26.7% to $1.40 in pre-market trading after falling 9% on Thursday.
  • Onconetix, Inc. (NASDAQ: ONCO) shares fell 19.5% to $0.2737 in pre-market trading after surging around 130% on Thursday,
  • Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares fell 15.8% to $0.1895 in pre-market trading after the company announced a 1-for-12 reverse stock split.
  • C3is Inc. (NASDAQ: CISS) declined 13.6% to $0.1384 in pre-market trading after gaining over 20% on Thursday. C3is recently announced pricing of its $7 million upsized underwritten public offering.
  • Revelation Biosciences, Inc. (NASDAQ: REVB) fell 12.8% to $9.07 in pre-market trading after declining around 13% on Thursday.
  • Planet Image International Limited (NASDAQ: YIBO) fell 12.2% to $2.45 after dipping 30% on Thursday. Planet Image International priced its initial public offering of 1.25 million ordinary shares at $4 per share.
  • Intel Corporation (NASDAQ: INTC) shares declined 11.4% to $43.89 in pre-market trading. Intel reported upbeat results for its fourth quarter, but issued a weak forecast for the first quarter.
  • American Rebel Holdings, Inc. (NASDAQ: AREB) shares fell 10.2% to $0.3367 in pre-market trading after jumping over 41% on Thursday.
  • KLA Corporation (NASDAQ: KLAC) shares declined 7.5% to $593.50 in pre-market trading after the company reported second-quarter financial results and issued third-quarter guidance.
  • Western Digital Corporation (NASDAQ: WDC) shares dipped 5.2% to $57.20 in pre-market trading. Western Digital reported better-than-expected earnings and sales results for its second quarter.

Now Read This: Jim Cramer: This Healthcare Stock Is 'Too Risky,' But Shares Jumped 64% Over Past Month

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.